Importantly, through in vitro and in vivo studies, we demonstrated that depletion of FGL1 inhibits ESCC cell metastasis, highlighting the potential of FGL1 depletion in enhancing patient survival and the development of novel therapeutic targets. Here, FGL1 is linked to esophageal squamous cell carcinoma.